New Three-Drug cocktail aims to tame relapsed myeloma
NCT ID NCT04094961
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of three oral drugs—ixazomib, pomalidomide, and dexamethasone—given twice weekly to people whose multiple myeloma has returned or stopped responding to prior treatments. The goal is to find a safe and effective dose that controls the cancer. The trial enrolls 52 participants and is currently active but no longer recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ixazomib (Ninlaro), Pomalidomide (Pomalyst), and Dexamethasone
What this could lead to
If successful, this could offer a new, more convenient oral combination to control multiple myeloma that has returned or stopped responding to other treatments.
What could go wrong
This is an early-phase trial with only 52 participants, so results may not apply to all patients. Side effects from the drug combination could be significant, and the regimen may not prove more effective than existing options.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States